ARMED WITH PROPEL

PROPEL®
MOMETASONE FUROATE SINUS IMPLANTS

YOUR ACTION PLAN FOR
MAXILLARY SINUS

Only PROPEL Contour combines mechanical spacing and localized drug delivery to the maxillary sinus, thereby maintaining sinus patency[1]



PROPEL Contour delivery system

- Hourglass-shaped implant
- Indicated for the frontal and/or maxillary sinus ostia
- Optimal for an hourglass-shaped frontal sinus opening

Surgery + PROPEL Contour provides benefits following maxillary sinus surgery[1,2]

- PROPEL Contour delivery success rate (primary endpoint) in maxillary sinuses was 95.2% (N=15)
- 100% maxillary sinus ostial patency (secondary endpoint) was achieved at Day 30 (N=15)
- Reduction in inflammation was observed at Day 90

Study Design: EXCEED was a 15-patient, prospective, single-arm, open-label feasibility trial. Patients were implanted with PROPEL Contour into the maxillary sinus ostia following sinus surgery with traditional instrumentation, balloon dilation, or a hybrid of both.[3]

For significant improvements to patient outcomes following sinus surgery, add PROPEL Contour to your battle for the maxillary sinus*

ESS, endoscopic sinus surgery.
*Representative outcomes of a single patient from an EXCEED clinical study. Individual results may vary.

Optimal treatment following maxillary sinus surgery with a full arsenal of options, including PROPEL Contour, can help improve patient outcomes.

The PROPEL Contour sinus implant is indicated to maintain patency of the frontal and maxillary sinus ostia and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

References: 1. PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016. **2.** Data on file. Intersect ENT, Inc. EXCEED clinical study report. Study #P500-0414, Doc #R 28019 Rev. 1.0, March 28, 2016. **3.** ClinicalTrials.gov. Clinical evaluation of PROPEL Nova Sinus Implant in peripheral sinus ostia (EXCEED). https://clinicaltrials.gov/ct2/show/NCT02228720?term=exceed+propel&rank=1. Accessed June 24, 2019.

For more information, visit PROPELOpens.com

PROPEL® contour
MOMETASONE FUROATE IMPLANT

MPM-11531 Rev 1.0